These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28070984)

  • 1. An approach for sample size determination of average bioequivalence based on interval estimation.
    Chiang C; Hsiao CF
    Stat Med; 2017 Mar; 36(7):1068-1082. PubMed ID: 28070984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalence assessment for interchangeability based on two-sided tests.
    Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical approach for comparing means of two groups without equal variance assumption.
    Wang H; Chow SC
    Stat Med; 2002 Oct; 21(20):3137-51. PubMed ID: 12369087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.
    Maurer W; Jones B; Chen Y
    Stat Med; 2018 May; 37(10):1587-1607. PubMed ID: 29462835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exact calculation of power and sample size in bioequivalence studies using two one-sided tests.
    Shen M; Russek-Cohen E; Slud EV
    Pharm Stat; 2015; 14(2):95-101. PubMed ID: 25477145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An approximate approach to sample size determination in bioequivalence testing with multiple pharmacokinetic responses.
    Tsai CA; Huang CY; Liu JP
    Stat Med; 2014 Aug; 33(19):3300-17. PubMed ID: 24771655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Power Analysis and Sample Size Determination for Crossover Trials with Application to Bioequivalence Assessment of Topical Ophthalmic Drugs Using Serial Sampling Pharmacokinetic Data.
    Yu YP; Yan XY; Yao C; Xia JL
    Biomed Environ Sci; 2019 Aug; 32(8):614-623. PubMed ID: 31488237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of variability and carryover on average bioequivalence assessment: a simulation study.
    Sánchez MP; Ocaña J; Carrasco JL
    Pharm Stat; 2011; 10(2):135-42. PubMed ID: 22432131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of interval estimations in design and evaluation of multiregional clinical trials with continuous outcomes.
    Chiang C; Hsiao CF
    Stat Methods Med Res; 2019 Jul; 28(7):2179-2195. PubMed ID: 29355082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size determination for equivalence assessment with multiple endpoints.
    Sun A; Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1203-14. PubMed ID: 25032845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small sample confidence interval approach to assess individual bioequivalence.
    Hyslop T; Hsuan F; Holder DJ
    Stat Med; 2000 Oct; 19(20):2885-97. PubMed ID: 11033583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalence tests for ratio of means in bioequivalence studies under crossover design.
    He Y; Deng Y; You C; Zhou XH
    Stat Methods Med Res; 2022 Jul; 31(7):1405-1419. PubMed ID: 35422161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalence tests for interchangeability based on two one-sided probabilities.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2014; 24(6):1332-48. PubMed ID: 25033074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs.
    Jaki T; Pallmann P; Wolfsegger MJ
    Stat Med; 2013 Dec; 32(30):5469-83. PubMed ID: 23801551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First measured plasma concentration value as C(max); impact on the C(max) confidence interval in bioequivalence studies.
    Jackson A; Conner D; Miller R
    Biopharm Drug Dispos; 2000 May; 21(4):139-46. PubMed ID: 11180192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance intervals for assessing individual bioequivalence.
    Brown EB; Iyer HK; Wang CM
    Stat Med; 1997 Apr; 16(7):803-20. PubMed ID: 9131767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing for bioequivalence of highly variable drugs from TR-RT crossover designs with heterogeneous residual variances.
    Kang Q; Vahl CI
    Pharm Stat; 2017 Sep; 16(5):361-377. PubMed ID: 28620937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two one-sided tests procedure for assessment of individual bioequivalence.
    Liu J; Chow SC
    J Biopharm Stat; 1997 Mar; 7(1):49-61. PubMed ID: 9056588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On statistical power for average bioequivalence testing under replicated crossover designs.
    Wan H; Chow SC
    J Biopharm Stat; 2002 Aug; 12(3):295-309. PubMed ID: 12448572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.